These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15791501)

  • 1. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
    Ozyuvaci E; Altan A; Demir C
    Agri; 2005 Jan; 17(1):49-53. PubMed ID: 15791501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer.
    Heidenreich A; Hofmann R; Engelmann UH
    J Urol; 2001 Jan; 165(1):136-40. PubMed ID: 11125382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Randomized trial of two administration schedule of bonephos (Clodronate) in patients with painful bone metastasis].
    Moiseenko VM; Blinov NN; Semiglazov VV; Konstantinova MM; Trishkina EA
    Vopr Onkol; 1998; 44(6):725-8. PubMed ID: 10087976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of bisphosphonates can dramatically improve pain in advanced hormone-refractory prostate cancer patients.
    Rodrigues P; Hering F; Campagnari JC
    Prostate Cancer Prostatic Dis; 2004; 7(4):350-4. PubMed ID: 15534620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The analgesic efficacy of clodronate compared with placebo in patients with painful bone metastases from prostatic cancer.
    Strang P; Nilsson S; Brändstedt S; Sehlin J; Borghede G; Varenhorst E; Bandman U; Borck L; Englund G; Selin L
    Anticancer Res; 1997; 17(6D):4717-21. PubMed ID: 9494595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
    Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
    J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer.
    Kylmälä T; Tammela TL; Lindholm TS; Seppänen J
    Ann Chir Gynaecol; 1994; 83(4):316-9. PubMed ID: 7537482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
    Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
    J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disodium clodronate in the treatment of pain due to bone metastases.
    Luzzani M; Vidili MG; Rissotto R; Nobile MT; Beghè F; Rosso R; Gottlieb A
    Int J Clin Pharmacol Res; 1990; 10(4):243-6. PubMed ID: 2150406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study.
    Varenna M; Zucchi F; Ghiringhelli D; Binelli L; Bevilacqua M; Bettica P; Sinigaglia L
    J Rheumatol; 2000 Jun; 27(6):1477-83. PubMed ID: 10852274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transient relief of metastatic cancer bone pain by oral administration of etidronate.
    Iwamoto J; Takeda T; Ichimura S
    J Bone Miner Metab; 2002; 20(4):228-34. PubMed ID: 12115069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain.
    Ernst DS; Brasher P; Hagen N; Paterson AH; MacDonald RN; Bruera E
    J Pain Symptom Manage; 1997 Jun; 13(6):319-26. PubMed ID: 9204651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: a 23-day, prospective, double-blind, randomized, parallel-group study.
    Rodriguez RF; Castillo JM; Del Pilar Castillo M; Nuñez PD; Rodriguez MF; Restrepo JM; Rodriguez JM; Ortiz Y; Angel AM
    Clin Ther; 2007 Apr; 29(4):581-7. PubMed ID: 17617281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
    Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer and bone metastases. The effect of clodronate.
    Kylmälä T
    Ann Chir Gynaecol; 1998; 87(1):59-60. PubMed ID: 9598233
    [No Abstract]   [Full Text] [Related]  

  • 18. A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 Trial).
    Dearnaley DP; Sydes MR; Mason MD; Stott M; Powell CS; Robinson AC; Thompson PM; Moffat LE; Naylor SL; Parmar MK;
    J Natl Cancer Inst; 2003 Sep; 95(17):1300-11. PubMed ID: 12953084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer.
    Ueda T; Suzuki H; Akakura K; Ishihara M; Kamiya N; Komiya A; Shimbo M; Suyama T; Sakamoto S; Ichikawa T
    Hinyokika Kiyo; 2006 Jul; 52(7):515-21. PubMed ID: 16910582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of bisphosphonates in palliative treatment of bone metastases in a terminally ill, oncological elderly population.
    Santangelo A; Testai M; Barbagallo P; Manuele S; Di Stefano A; Tomarchio M; Trizzino G; Musumeci G; Panebianco P; Maugeri D
    Arch Gerontol Geriatr; 2006; 43(2):187-92. PubMed ID: 16325938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.